Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
204 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2016', provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics and enlists all their major and minor projects - The report assesses Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Relapsing Remitting Multiple Sclerosis (RRMS) Overview 11 Therapeutics Development 12 Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview 12 Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis 13 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies 14 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes 16 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies 20 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes 23 Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development 24 AB Science SA 24 AbbVie Inc. 25 Actelion Ltd 26 Alkermes Plc 27 Amarna Therapeutics B.V. 28 Antisense Therapeutics Limited 29 Biocon Limited 30 Biogen, Inc. 31 Cognosci, Inc. 32 F. Hoffmann-La Roche Ltd. 33 Forward Pharma A/S 34 GeNeuro SA 35 GlaxoSmithKline Plc 36 Iltoo Pharma 37 InteKrin Therapeutics, Inc. 38 Mapi Pharma Ltd. 39 MedImmune, LLC 40 Merck KGaA 41 Mitsubishi Tanabe Pharma Corporation 42 Neurotec Pharma SL 43 Novartis AG 44 Octapharma AG 45 Opexa Therapeutics, Inc. 46 RedHill Biopharma Ltd. 47 Teva Pharmaceutical Industries Ltd. 48 Xenetic Biosciences (UK) Limited 49 Zydus Cadila Healthcare Limited 50 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Combination Products 52 Assessment by Target 53 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 (clarithromycin + clofazimine + rifabutin) - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 aldesleukin - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ALKS-8700 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 amiselimod hydrochloride - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ATL-1102 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 AZ-17 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Cellular Immunotherapy for Relapsing Remitting Multiple Sclerosis - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 cladribine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 COG-133 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 daclizumab - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 diazoxide - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 dimethyl fumarate - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 glatiramer acetate ER - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 GNbAC-1 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 GSK-239512 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Guanabenz - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 HR-411 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 hydralazine - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 IB-MS - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 imilecleucel-t - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 immune globulin (human) - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 inebilizumab - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 INT-131 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 interferon beta-1b - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 interferon beta-1b - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 itolizumab - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 laquinimod sodium - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 M-2736 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 masitinib - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 MyeloXen - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 ocrelizumab - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 ofatumumab - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 opicinumab - Drug Profile 130 Product Description 130 Mechanism of Action 130 R&D Progress 130 Pegylated Interferon-Beta-1b - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 ponesimod - Drug Profile 133 Product Description 133 Mechanism of Action 133 R&D Progress 133 siponimod - Drug Profile 135 Product Description 135 Mechanism of Action 135 R&D Progress 135 Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 137 Product Description 137 Mechanism of Action 137 R&D Progress 137 Xemys - Drug Profile 138 Product Description 138 Mechanism of Action 138 R&D Progress 138 Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates 140 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 187 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products 189 Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 190 Featured News & Press Releases 190 Apr 12, 2016: Teva to Present Data on laquinimod at 68th AAN Annual Meeting 190 Mar 31, 2016: RedHill Announces Interim Results from Phase IIa PoC Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis 190 Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 194 Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 196 Jun 25, 2015: Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial 197 Jun 09, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis 198 Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 198 Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis 200 Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 200 Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 202 Appendix 203 Methodology 203 Coverage 203 Secondary Research 203 Primary Research 203 Expert Panel Validation 203 Contact Us 203 Disclaimer 204
List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2016 12 Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AB Science SA, H1 2016 24 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H1 2016 25 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H1 2016 26 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Alkermes Plc, H1 2016 27 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H1 2016 28 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H1 2016 29 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biocon Limited, H1 2016 30 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H1 2016 31 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H1 2016 32 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 33 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H1 2016 34 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GeNeuro SA, H1 2016 35 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline Plc, H1 2016 36 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H1 2016 37 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by InteKrin Therapeutics, Inc., H1 2016 38 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H1 2016 39 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H1 2016 40 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H1 2016 41 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 42 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H1 2016 43 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H1 2016 44 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H1 2016 45 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H1 2016 46 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H1 2016 47 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 48 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 49 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 50 Assessment by Monotherapy Products, H1 2016 51 Assessment by Combination Products, H1 2016 52 Number of Products by Stage and Target, H1 2016 54 Number of Products by Stage and Mechanism of Action, H1 2016 58 Number of Products by Stage and Route of Administration, H1 2016 61 Number of Products by Stage and Molecule Type, H1 2016 63 Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H1 2016 140 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H1 2016 187 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H1 2016 188 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H1 2016 189
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
